Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Glucagon-like Peptide-2 replacement therapy for neonatal piglets with short bowel syndrome: Does the terminal ileum matter?

FY 2010-11

Summary
Short bowel syndrome is defined as inadequate bowel length to absorb enough nutrition to survive and grow. Short bowel syndrome can occur in babies after surgery for bowel disorders following birth. These babies need intravenous nutrition to survive, which can cause life-threatening complications such as infections and severe liver disease. The quality of life for these babies and their families is poor, and the cost to society for medical support is high. If we were able to promote the growth and development of the shortened bowel for these babies, we could reduce their need to continue intravenous nutrition and decrease their risk of developing the associated complications. One potential therapy is the use of a bowel-derived growth hormone, glucagon-like peptide-2 (GLP-2), that is known to increase intestinal growth and function, and which we believe is deficient in these babies. In order to develop this potential new treatment, we propose that it should be studied in animals first. This project will test the effect of GLP-2 on piglets that have undergone intestinal surgery to create the condition of short bowel syndrome. We will assess several outcomes after treatment of the animals with GLP-2. In addition to clinical outcomes such as bowel growth and tolerance of intestinal feeds, we will also assess adaptive changes to the intestine microscopically and markers of liver disease. It is hoped that this research will lead to important advances in our knowledge of the potential for GLP-2 to treat this very serious condition.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
225373
Name
Suri Megha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Glucagon-like Peptide-2 replacement therapy for neonatal piglets with short bowel syndrome: Does the terminal ileum matter?
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biostatistics; Gastroenterology; General Surgery; Laboratory Animal Medicine; Nutrition And Metabolism; Pediatric Surgery; Translational Research
Abstract
Short bowel syndrome is defined as inadequate bowel length to absorb enough nutrition to survive and grow. Short bowel syndrome can occur in babies after surgery for bowel disorders following birth. These babies need intravenous nutrition to survive, which can cause life-threatening complications such as infections and severe liver disease. The quality of life for these babies and their families is poor, and the cost to society for medical support is high. If we were able to promote the growth and development of the shortened bowel for these babies, we could reduce their need to continue intravenous nutrition and decrease their risk of developing the associated complications. One potential therapy is the use of a bowel-derived growth hormone, glucagon-like peptide-2 (GLP-2), that is known to increase intestinal growth and function, and which we believe is deficient in these babies. In order to develop this potential new treatment, we propose that it should be studied in animals first. This project will test the effect of GLP-2 on piglets that have undergone intestinal surgery to create the condition of short bowel syndrome. We will assess several outcomes after treatment of the animals with GLP-2. In addition to clinical outcomes such as bowel growth and tolerance of intestinal feeds, we will also assess adaptive changes to the intestine microscopically and markers of liver disease. It is hoped that this research will lead to important advances in our knowledge of the potential for GLP-2 to treat this very serious condition.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Suri, Megha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~